Teva Loses Inhaler Patent Case Against Amneal, Must Delete or Amend Orange Book Listing

A New Jersey federal court on Monday ruled against Teva Pharmaceuticals, finding that five key patents for its inhaler product ProAir HFA (albuterol sulfate) are “improperly listed” on the FDA’s Orange Book.